Igor Bilinsky
Chief Operating Officer chez IOVANCE BIOTHERAPEUTICS, INC.
Fortune : 563 545 $ au 31/03/2024
Profil
Igor P. Bilinsky occupe le poste de directeur de l'exploitation d'Iovance Biotherapeutics, Inc. Auparavant, le Dr Bilinsky a occupé les postes de directeur général chez Androclus Therapeutics, Inc, de vice-président chargé du développement commercial et des opérations spéciales chez Halozyme Therapeutics, Inc, de directeur chez The Boston Consulting Group, Inc, de directeur commercial chez Oncternal Therapeutics, Inc, directeur de l'exploitation et vice-président principal d'AmpliPhi Biosciences Corp, chef de la recherche et du développement de Symyx Technologies, Inc, vice-président principal du développement de l'entreprise de Vical, Inc et vice-président principal des opérations spéciales, directeur général de l'immunologie et de l'oncologie d'Ignyta, Inc. Igor P. Bilinsky a obtenu un diplôme de premier cycle à l'Institut de physique et de technologie de Moscou et un doctorat au Massachusetts Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2024 | 38 026 ( 0,01% ) | 563 545 $ | 31/03/2024 |
Postes actifs de Igor Bilinsky
| Sociétés | Poste | Début |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Chief Operating Officer | 15/03/2021 |
Anciens postes connus de Igor Bilinsky
| Sociétés | Poste | Fin |
|---|---|---|
| ONCTERNAL THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2021 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Chief Operating Officer | 14/01/2019 |
| IGNYTA INC | Corporate Officer/Principal | 01/01/2017 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2010 |
| Androclus Therapeutics, Inc. | Chief Executive Officer | 01/01/2007 |
Formation de Igor Bilinsky
| Massachusetts Institute of Technology | Doctorate Degree |
| Moscow Institute of Physics & Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| ONCTERNAL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Symyx Technologies, Inc.
 Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Technology Services |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
| Androclus Therapeutics, Inc. | |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
